Has R&D Productivity Rebounded? US FDA Officials Think So
Executive Summary
Record-setting pace of NME approvals is a cause for celebration. But is it a sign that drug industry R&D productivity has actually improved? The US FDA’s top drug review official thinks so – but the data aren’t yet clear.
You may also be interested in...
US FDA’s Record Year For Drug Approvals? Wall Street Is Unimpressed
Pace of new US drug approvals is unprecedented, but investors continue to shun biopharma industry. Uncertainty about pricing environment is clearly outweighing the favorable regulatory climate. Stocks in the sector closed the year down more than 15% are still trading well below 2015 levels.
US FDA's Robert Temple And Signatory Authority: Teacher And Back-Up
The widely respected agency veteran will still be able to sign off on applications in his new "consultant" role in the Office of New Drugs, in part to help with the increasing workload.
Mehta Analysis: Outlook For 2029
Looking forward means playing the long game in biopharma. In a decade's time, it will all be about knowing every protein the AI way, something which will have transformed the industry, believes Viren Mehta, founding partner of Mehta Partners LLC.